Moderna to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

Rhea-AI Summary

Moderna (Nasdaq: MRNA) announced that President Stephen Hoge, M.D., will join a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5 at 1:00 p.m. ET. Investors can access a live webcast of the event on Moderna's website under “Events and Presentations.” The discussion will be archived for 30 days post-event. Moderna has evolved significantly in its 10 years, focusing on mRNA therapeutics and vaccines, including COVID-19, and has built a diverse clinical portfolio alongside robust manufacturing capabilities.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at Chardan’s Virtual 5^th Annual Genetic Medicines Conference on Tuesday, October 5^th at 1:00 p.m. ET.

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005689/en/

Investors:

Lavina Talukdar

Senior Vice President & Head of Investor Relations

617-209-5834

Lavina.Talukdar@modernatx.com

Source: Moderna, Inc.

FAQ

When is the fireside chat with Stephen Hoge from Moderna?

The fireside chat with Stephen Hoge is scheduled for October 5 at 1:00 p.m. ET.

How can I watch the Moderna fireside chat?

You can watch the Moderna fireside chat live on their website under 'Events and Presentations'.

What is Moderna's focus in biotechnology?

Moderna focuses on messenger RNA (mRNA) therapeutics and vaccines, including those for COVID-19.

Where can I find the replay of the Moderna conference presentation?

A replay of the Moderna conference presentation will be available on their website for 30 days following the event.

What significant developments has Moderna achieved in its 10 years?

In 10 years, Moderna has developed a diverse portfolio in mRNA vaccines and therapeutics, including effective COVID-19 vaccines.